However, despite this progress, only about 20-30% of HNSCC cases survived after anti-PD-1/PD-L1 therapies, and the response towards PD-1/PD-L1 blockade is still far from satisfactory. The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.